AUR-103 / Dr. Reddy’s - LARVOL DELTA

PK, PD AND SAFETY OF FIRST-IN-HUMAN, FIRST-IN-CLASS PHASE I TRIAL (AUR103-101; BHARAT) OF AUR103, AN ORAL CD47 INHIBITOR, IN PATIENTS WITH ADVANCED MALIGNANCIES (EHA 2023) - P1 | "Subsequent to determining the OBD of single agent AUR103, combination studies with azacitidine and/or azacitidine/Venetoclax and/or ADCC competent antibodies will be studied in relevant tumor types. AUR103 is a novel First in Class small molecule inhibitor of CD47. The First in Human trial (AUR103-101; BHARAT) is currently enrolling. The preliminary safety in the first two cohorts appears commensurate with "lack of haemolysis" in non-clinical models."

Clinical • Metastases • P1 data • Acute Myelogenous Leukemia • Anemia • Anorexia • Hematological Disorders • Musculoskeletal Pain • Oncology • Pain • Pruritus • CD47 • SIRPA

BHARAT-1: A First in Human Study of AUR 103 Calcium to Evaluate Safety, Pharmacokinetics and Pharmacodynamics (clinicaltrials.gov) - P1 | N=80 | Recruiting | Sponsor: Aurigene Discovery Technologies Limited

New P1 trial • Acute Myelogenous Leukemia • Follicular Lymphoma • Hematological Malignancies • Indolent Lymphoma • Leukemia • Lymphoma • Mantle Cell Lymphoma • Myelodysplastic Syndrome • Non-Hodgkin’s Lymphoma • Oncology • Solid Tumor